Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Expression of Type IV Collagen, Metalloproteinase-2, Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Laryngeal Squamous Cell Carcinomas

Cao, Xiao-Lin;Xu, Ru-Jun;Zheng, You-Yang;Liu, Jun;Teng, Yao-Shu;Li, Yong;Zhu, Jin

  • Published : 20111200
⟨ Previous Next ⟩

Abstract

Objective: To investigate the significance of type IV collagen, metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) expression in laryngeal squamous cell carcinomas (LSCCs). Methods: Expression was quantified in 44 LSCC and 22 adjacent non-cancer normal tissues using a streptavidin-peroxidase conjugated immunohistochemistry and associations between the levels of the four proteins and clinicopathological characteristics in LSCC were analyzed. Results: Significantly different expression of all four proteins was observed in LSCC and adjacent non-cancer normal tissues (P<0.05). Expression of type IV collagen correlated with primary cancer status (P = 0.04), clinical stage (P = 0.04) and histological grade (P = 0.01). Expression of MMP-9 correlated with the location of the tumor (P = 0.04), cervical node metastasis (P = 0.02) and prognosis (P = 0.02). The (MMP-2+MMP-9)/TIMP-1 score was associated with the prognosis of LSCC (P < 0.01). Conclusions: This study suggests that expression of type IV collagen and its regulators is strongly associated with the development of LSCC. Type IV collagen and MMP-9 may be more valuable than MMP-2 and TIMP-1 for the evaluation of clinical characteristics. Regulation of type IV collagen may contribute to the balance of MMPs and TIMPs in LSCC.

Keywords

References

  1. Aref S, Osman E, Mansy S, et al (2007). Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol, 25, 121-6. https://doi.org/10.1002/hon.817
  2. Courey MS, Shohet JA, Scott MA, Ossoff RH (1996). Immunohistochemical characterization of benign laryngeal lesions. Ann Otol Rhinol Laryngol, 105, 525-31.
  3. Dong W, Li H, Zhang Y, et al (2011). Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 2011 Oct 3.
  4. Franchi A, Santucci M, Masini E, et al (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95, 1902-10. https://doi.org/10.1002/cncr.10916
  5. Figueira RC, Gomes LR, Neto JS, et al (2009). Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 9, 20. https://doi.org/10.1186/1471-2407-9-20
  6. Gandini S, Botteri E, Iodice S, et al (2008). Tobacco smoking and cancer: a meta-analysis. Int J Cancer, 122, 155-64. https://doi.org/10.1002/ijc.23033
  7. Gomez DE, Alonso DF, Yoshiji H (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 74, 111-5.
  8. Islami F, Tramacere I, Rota M, et al (2010). Alcohol drinking and laryngeal cancer: overall and dose-risk relation-a systematic review and meta-analysis. Oral Oncol, 46, 802-10. https://doi.org/10.1016/j.oraloncology.2010.07.015
  9. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004). The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol, 50, 87-100. https://doi.org/10.1016/j.critrevonc.2003.09.001
  10. Kondratiev S, Gnepp DR, Yakirevich E, et al (2008). Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum Pathol, 39, 337-43. https://doi.org/10.1016/j.humpath.2007.07.003
  11. Krecicki T, Fraczek M, Jelen M, et al (2003). Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol, 260, 494-7. https://doi.org/10.1007/s00405-003-0610-2
  12. Krecicki T, Zalesska-Krecicka M, Jelen M, et al (2001). Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clin Otolaryngol, 26, 469-72. https://doi.org/10.1046/j.0307-7772.2001.00503.x
  13. Kugler A, Hemmerlein B, Thelen P, et al (1988). Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol, 160, 1914-8.
  14. Leblond CP, Inoue S (1989). Structure, composition and assembly of basement membrane. Am J Anat, 185, 367-90. https://doi.org/10.1002/aja.1001850403
  15. Liotta LA, Rao CN, Barsky SH (1983). Tumor invasion and the extracellular matrix. Lab Invest, 49, 636-49.
  16. Maestro R, Dolcetti R, Gasparotto D, et al (1992). High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 7, 1159-66.
  17. Martins RH, Defaveri J, Custodio Domingues MA, et al (2010). Vocal fold nodules: morphological and immunohistochemical investigations. J Voice, 24, 531-9. https://doi.org/10.1016/j.jvoice.2009.01.002
  18. Marur S, D'Souza G, Westra WH, Forastiere AA (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11, 781-9. https://doi.org/10.1016/S1470-2045(10)70017-6
  19. Molica S, Vitelli G, Levato D, et al (2003). Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. EurJ Haematol, 70, 373-8. https://doi.org/10.1034/j.1600-0609.2003.00064.x
  20. Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52, 255-64. https://doi.org/10.1046/j.1440-1827.2002.01343.x
  21. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000). Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18, 1135-49.
  22. Overall CM, Lopez-Otin C (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer, 2, 657-72. https://doi.org/10.1038/nrc884
  23. Peschos D, Damala C, Stefanou D, et al (2006). Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol, 21, 603-8.
  24. Rosenthal EL, Johnson TM, Allen ED, et al (1998). Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res, 58, 5221-30.
  25. Shi Y, Parhar RS, Zou M, et al (1999). Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma. Br J Cancer, 79, 1234-9. https://doi.org/10.1038/sj.bjc.6690198
  26. Suminoe A, Matsuzaki A, Hattori H, et al (2007). Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res, 31, 1437-40. https://doi.org/10.1016/j.leukres.2007.01.015
  27. Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. EurJ Haematol, 80, 216-26. https://doi.org/10.1111/j.1600-0609.2007.01012.x
  28. Trudel D, Fradet Y, Meyer F, Tetu B (2010). Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol, 41, 1694-701. https://doi.org/10.1016/j.humpath.2010.05.001
  29. Wang Y, Sun WY, Guan C, et al (2011). Distribution of basement membrane in supraglottic carcinoma. Pathol Oncol Res, 17, 1-5. https://doi.org/10.1007/s12253-010-9250-1
  30. Wittekindt C, Jovanovic N, Guntinas-Lichius O (2011). Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol, 131, 101-6. https://doi.org/10.3109/00016489.2010.506886
  31. Woessner JF Jr (1994). The family of matrix metalloproteinases. Ann N Y Acad Sci, 732, 11-21. https://doi.org/10.1111/j.1749-6632.1994.tb24720.x
  32. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.